Literature DB >> 8301429

Delta 4-3-oxosteroid 5 beta-reductase deficiency causing neonatal liver failure and hemochromatosis.

B L Shneider1, K D Setchell, P F Whitington, K A Neilson, F J Suchy.   

Abstract

Neonatal liver failure was evaluated in two infants. Neither infant had evidence of congenital infection, galactosemia, alpha 1-antitrypsin deficiency, tyrosinemia, Zellweger syndrome, or hemophagocytic lymphohistiocytosis. Abnormal levels of iron were detected in the minor salivary glands of the first infant and in the explanted liver of the second. Analyses of urinary bile salts by fast-atom bombardment ionization mass spectrometry and gas chromatography-mass spectrometry revealed a paucity of primary bile acids and a predominance of 7 alpha-hydroxy-3-oxo-4-cholenoic and 7 alpha,12 alpha-dihydroxy-3-oxo-4-cholenoic acids. These findings are consistent with delta 4-3-oxosteroid 5 beta-reductase deficiency, a primary genetic defect in bile acid synthesis. Postmortem evaluation of the first infant revealed significant iron deposition in the liver, pancreas, thyroid, adrenal glands, myocardium, stomach, and submucosal glands of the respiratory tract. In both infants examination of the liver revealed extensive loss of hepatic parenchyma. These cases expand the clinical spectrum of bile acid metabolism defects to include neonatal liver failure with associated hemochromatosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8301429     DOI: 10.1016/s0022-3476(94)70310-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

1.  Identification of neonatal liver failure and perinatal hemochromatosis in Canada.

Authors:  R Jackson; E A Roberts
Journal:  Paediatr Child Health       Date:  2001-05       Impact factor: 2.253

Review 2.  Neonatal hemochromatosis.

Authors:  Amy G Feldman; Peter F Whitington
Journal:  J Clin Exp Hepatol       Date:  2013-11-27

3.  [Clinical feature and genetic analysis of a family affected by congenital bile acid synthesis defect type 2: identification of 2 novel mutations in AKR1D1 gene].

Authors:  Ying Cheng; Li Guo; Mei Deng; Yuan-Zong Song
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-07

4.  Recurrence of neonatal haemochromatosis in half sibs born of unaffected mothers.

Authors:  A Verloes; I K Temple; A F Hubert; P Hope; S Gould; C Debauche; G Verellen; J L Deville; L Koulischer; E M Sokal
Journal:  J Med Genet       Date:  1996-06       Impact factor: 6.318

5.  Classification and genetic features of neonatal haemochromatosis: a study of 27 affected pedigrees and molecular analysis of genes implicated in iron metabolism.

Authors:  A L Kelly; P W Lunt; F Rodrigues; P J Berry; D M Flynn; P J McKiernan; D A Kelly; G Mieli-Vergani; T M Cox
Journal:  J Med Genet       Date:  2001-09       Impact factor: 6.318

6.  Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy.

Authors:  H A Lemonde; E J Custard; J Bouquet; M Duran; H Overmars; P J Scambler; P T Clayton
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

7.  Diagnosis of the first Japanese patient with 3-oxo-delta4-steroid 5beta-reductase deficiency by use of immunoblot analysis.

Authors:  A Kimura; K H Kondo; K I Okuda; S Higashi; M Suzuki; T Kurosawa; M Tohma; T Inoue; A Nishiyori; M Yoshino; H Kato; T Setoguchi
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

Review 8.  Mechanisms of disease: Inborn errors of bile acid synthesis.

Authors:  Shikha S Sundaram; Kevin E Bove; Mark A Lovell; Ronald J Sokol
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-06-24

Review 9.  New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients.

Authors:  Dominique Debray; Nadya Yousef; Philippe Durand
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 10.  Bile acid metabolism and signaling.

Authors:  John Y L Chiang
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.